title: [Treatment of type 2 diabetes in the elderly].
abstract: Treatment of type 2 diabetes in the elderly represents a major challenge both in terms of clinical management and public health. Aging is causing a marked increase in the pandemic of diabetes in elderly people. However, scientific evidence to support the most appropriate treatment for diabetes in the elderly is scarce. Given the heterogeneity of the elderly population, which includes subjects with very different functional and cognitive capacities, co-morbidities, and life expectancy, it is critical to make a comprehensive assessment from a biopsychosocial perspective, to address the vascular risk factors integrally, and to establish individually tailored targets for glycemic control. In frail elderly or individuals with a short life expectancy, it may be reasonable to maintain HbA1c between 7.6%-8.5%. The therapeutic strategy for elderly patients with type 2 diabetes should be individualized and agreed with the patient and their caregivers, according to the objective. Improving quality of life, assuring patient safety and avoiding the adverse effects of antidiabetic treatment should be prioritized. Given the increased susceptibility of the elderly to severe hypoglycemia and its consequences, antidiabetic therapies that minimize the risk of hypoglycemic events should be selected.
authors.affiliation: Sociedad Española de Medicina Interna (SEMI). ricardogomezhuelgas@hotmail.com
authors.forename: Ricardo
authors.initials: R
authors.lastname: Gómez Huelgas
authors.forename: Javier
authors.initials: J
authors.lastname: Díez-Espino
authors.forename: Francesc
authors.initials: F
authors.lastname: Formiga
authors.forename: Javier
authors.initials: J
authors.lastname: Lafita Tejedor
authors.forename: Leocadio
authors.initials: L
authors.lastname: Rodríguez Mañas
authors.forename: Enrique
authors.initials: E
authors.lastname: González-Sarmiento
authors.forename: Edelmiro
authors.initials: E
authors.lastname: Menéndez
authors.forename: Javier
authors.initials: J
authors.lastname: Sangrós
mesh_terms: D000368:Aged; D000465:Algorithms; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003072:Cognition Disorders / Q000209:etiology / Q000517:prevention & control; D003131:Combined Modality Therapy; D015897:Comorbidity; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology / Q000523:psychology / Q000628:therapy*; D003927:Diet, Diabetic; D005081:Exercise Therapy; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use; D061266:Insulin, Short-Acting / Q000627:therapeutic use; D008019:Life Style; D008297:Male; D008875:Middle Aged; D019338:Polypharmacy; D011157:Population Dynamics; D015995:Prevalence; D011788:Quality of Life; D013030:Spain / Q000453:epidemiology
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D061266:Insulin, Short-Acting